DNA

ABLi Therapeutics Announces Details of the End of Phase 2 Meeting with FDA for Evaluation of Risvodetinib as a Treatment for Parkinson’s Disease

Agency supports primary and novel secondary and exploratory endpoints proposed for Phase 3 Trial(s) Opportunity to utilize time-to-delay of levodopa/carbidopa…

9 months ago

Konica Minolta Healthcare to Launch Integrated Teleradiology Solution Powered by NewVue

Exa Platform Konica Minolta Healthcare's Exa® Platform facilitates the viewing of large medical image files across the enterprise. TAMPA, Fla.…

9 months ago

Route 92 Medical Announces Results of SUMMIT MAX Clinical Trial Showing Highest First Pass Effect Ever Reported in a Randomized Endovascular Stroke Thrombectomy Study

Data from 250-patient, 31-center, randomized controlled trial presented at European Stroke Organisation Conference Three highest enrolling sites reported 96% delivery…

9 months ago

Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary

Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary New recruit expands senior team…

9 months ago

GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene…

9 months ago

IDENTIFYSENSORS INITIATES FDA SUBMISSION PROCESS FOR DIGITAL DIAGNOSTICS PLATFORM

Regulatory authorization will signal the first electronic technology to detect a disease CLEVELAND, May 20, 2025 /PRNewswire/ -- IdentifySensors Biologics,…

9 months ago

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

--Efficacy comparable to anti-IL4/IL13 antibody control --Achieved dose-dependent and durable target modulation in vivo without requiring degradation of STAT6 protein…

9 months ago

Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting

Presented new preclinical data in non-human primates (NHP) for alpha-1 antitrypsin deficiency (AATD) and phenylketonuria (PKU), where RNA Gene Writer…

9 months ago